Disclosures: takayuki tokunaga: Nothing to Disclose, Kazuhiro Sugi: Nothing to Disclose, Koichi Kudo: Nothing to Disclose, Yoshinari Sakai: Nothing to Disclose, Shiho Miyase: Nothing to Disclose, Kotaro Fukubayashi: Nothing to Disclose, Masakuni Tateyama: Nothing to Disclose, Kentaro Tanaka: Nothing to Disclose, Satoshi Narahara: Nothing to Disclose, Hiroki Inada: Nothing to Disclose, Etsuko Iio: Nothing to Disclose, Yoko Yoshimaru: Nothing to Disclose, Takehisa Watanabe: Nothing to Disclose, Katsuya Nagaoka: Nothing to Disclose, Hiroko Setoyama: Nothing to Disclose, Yasuhito Tanaka: Nothing to Disclose 1824 UBE2D3 NEGATIVELY REGULATES HEPATOCARCINOGENESIS VIA SUPPRESSION OF STAT3 SIGNALING Hideharu Nagasawa 1 Takahiro Kodama 2 Kazuki Maesaka 2 Kumiko Shirai 2 Akira Doi 2 Yuki Tahata 3 Yoshinobu Saito 4 Hayato Hikita 4 Tomohide Tatsumi 3 Tetsuo Takehara 3 , 1 Department of Gastroenterology and Hepatology, Graduate Scho, 2 University of Osaka, 3 Osaka University, 4 Osaka University Graduate School of Medicine Background: Pharmacotherapy for hepatocellular carcinoma (HCC) has progressed markedly in recent years, with many drugs becoming available
cGMP facilitates smooth muscle relaxation in blood vessels either by enhancing Ca 2+ extrusion or by reducing the sensitivity of the myofilaments to Ca 2+ [102]
Funding This research was supported by Scientific planning project of youth education in Shandong province Undergraduate Academic Project (23BSH251)
G.FredinS
(no photo available) 96 tests $974 KT-64012 Type-1 angiotensin II receptor (AGTR1) ELISA Kit, Human For quantitative detection in human samples
